Advanced prodrug approaches for neurodegenerative diseases

Abstract

The prodrug technique is still one of the most effective ways to increase hydrophilic substances' medicinal, pharmacodynamic and pharmacokinetic properties. Prodrugs produced in current history have shown good pharmacokinetic characteristics, allowing for a more consistent release and fewer changes in plasma levels. Developing new prodrugs having a desirable ADME (Absorption Distribution Metabolism and Elimination) properties and that still can cross the Blood brain barrier (BBB) and pharmacologically active an appealing task for medicinal chemists. The loss of brain neuron activity characterizes neurodegenerative illnesses, resulting in progressive Gradual cognitive impairment (GCI). Some of the common neurodegenerative diseases are PD (Parkinson's disease), AD (Alzheimer's disease), MS (Multiple sclerosis), ALS (amyotrophic lateral sclerosis) & HD (Huntington's disease) are examples of neurodegenerative illnesses with a variety of etiologies and morphological and pathophysiological aspects. The current review is concerned with current advances in prodrug approaches for the treatment and prevention of the most prevalent neurological illnesses, as well as their absorption, selective CNS targeting and chemical and enzymatic stability.